Breast Cancer Screening
description
Transcript of Breast Cancer Screening
![Page 1: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/1.jpg)
Breast Cancer Screening
• Steven Stanten MD
• Rupert Horoupian MD
AltaBates Summit Medical Center
Oakland, California
![Page 2: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/2.jpg)
Breast cancer incidence and mortality
England
France
Germany
Total EU
USA
n
10,846
10,811
17,692
73,592
39,800
n
34,176
35,726
48,098
210,631
211,300
Incidence Mortality
Jemal A et al. CA Cancer J Clin 2003; 53: 5–26; Cancer Research UK. Cancer Stats – Incidence & Mortality UK, April 2003;
Ferlay et al. IARC Press, 1999
![Page 3: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/3.jpg)
Incidence
• USA - 2008– 184,450 new cases of invasive ca– 40,930 deaths– 3 decade increase– Wide spread screening– Increased dx of non-invasive and pre-
malignant lesions
![Page 4: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/4.jpg)
BREAST CANCER BURDEN
• Breast cancer is the most common malignancy diagnosed in women (excluding cancers of the skin)
• In the United States breast cancer is the second most common cause of death from cancer
![Page 5: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/5.jpg)
• BREAST CANCER SCREENING IS AN INTEGRAL PART OF WOMEN’S PREVENTATIVE HEALTH
![Page 6: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/6.jpg)
Signs and Symptoms
• The earliest sign is an abnormality that shows up on a mammogram before it can be felt by the woman or health care provider.
• Early stages of breast cancer usually do not produce symptoms.
![Page 7: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/7.jpg)
Signs and Symptoms (Cont’d)
• When breast cancer grows to the point where physical symptoms exist, these may include:
- A painless mass (up to 10 percent of patients have breast pain and no mass).
- Breast changes: thickening, swelling, and skin irritation or distortion.
- Nipple changes: discharge, erosion, inversion, or tenderness.
![Page 8: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/8.jpg)
Treatment
• Treatment is most successful when the cancer is detected early, before it has spread.
• Treatment depends on the situation and the patient’s choices.
• Surgery
- Breast conservation surgery (lumpectomy) removes the tumor and surrounding tissue.
- Mastectomy removes the breast.
![Page 9: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/9.jpg)
Treatment (Cont’d)
• Radiation therapy
• Chemotherapy
• Hormone therapy
• Monoclonal antibody therapy
• Often, two or more methods are used in
• combination with each other.
![Page 10: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/10.jpg)
Mortality
• One in six diagnosed with breast ca will die from it
• Directly related to stage of disease
• Varies according to geography, culture, ethnicity, race and socioeconomic status
![Page 11: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/11.jpg)
Deaths
• An estimated 40,200 deaths will occur from breast cancer in 2003. More than 39,000 of these deaths will be among women.
• Only lung cancer accounts for more cancer deaths in women.
![Page 12: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/12.jpg)
Survival
0 20 40 60 80 100
Switzerland
Finland
France
Italy
Netherlands
Germany
Denmark
England
Spain
Scotland
Estonia
Poland
Five-year survival (%)
J Nat Cancer Inst 1995; 87: 1209J Nat Cancer Inst 1995; 87: 1209
5-year5-yearsurvival (%)survival (%)
No. ofNo. ofpatientspatients
75.775.773.573.571.471.470.870.869.969.968.468.468.168.162.562.562.562.561.861.858.858.843.943.9
2,2432,24311,12311,123
2,4982,4983,5953,5952,6532,6533,3593,359
17,49817,49860,39060,390
1,0431,04311,26111,261
2,3872,3871,0891,089
![Page 13: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/13.jpg)
![Page 14: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/14.jpg)
Survival
• Five-year localized survival rate…….97 percent
• Five-year regional survival rate…..…78 percent
• Five-year distant survival rate………21 percent
• Five-year overall survival rate….……86 percent
• Ten-year overall survival rate..………76 percent
![Page 15: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/15.jpg)
Risk Factors
• Direct– Age– Family hx– Early menarche– Late 1st birth– Proliferative benign breast disease– Thoracic radiation
![Page 16: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/16.jpg)
Risk Factors (con’t)
• Associations– Radiographically dense breasts
• Obesity• Alcohol intake• Menopausal hormone use
![Page 17: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/17.jpg)
Risk Factors
• As age increases, so does risk. Of all the women with breast cancer, 77 percent are 50+ years old.
• Genetic risk factors/personal or family history.• Early menarche (< 12 years) or late menopause
(>55 years).• Late age at first full-term pregnancy (> 30• years).
![Page 18: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/18.jpg)
Risk Factors (Cont’d)
• No children/not breast feeding = slight risk.
• Oral contraceptives use or hormone replacement therapy = slightly greater risk.
• Risks increase with alcohol consumption.
• Even moderate physical activity can decrease risk.
• Obesity = increased risk in post-menopausal women.
![Page 19: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/19.jpg)
Risk Factors for Breast Cancer
• Family History/genetic factors
• Reproductive/hormonal
• Proliferative benign breast disease
• Mammographic density
![Page 20: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/20.jpg)
Risk Assessment
• FACTORS USED IN NCI BREAST CANCER RISK PREDICTION MODEL -Age -Number of 1st degree female relatives with a
history of breast cancer -Number of breast biopsies -Age at first live birth or nulliparity -History of atypical hyperplasia -Age at menarche -Race
![Page 21: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/21.jpg)
Risk Assessment
• ORIGINAL GAIL MODEL• Gail et al Journal National Cancer Institute
1989; 81: 1879-1886• Model based and derived from extremely large
data sets• Estimates the risk of:
– invasive– in situ (DCIS)– or lobular carcinoma in situ (LCIS)– over a defined interval in women having annual
screening
![Page 22: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/22.jpg)
Risk Assessment
• LIMITATIONS OF GAIL MODEL –
MAY OVERPREDICT RISK IN PREMENOPAUSAL WOMEN WHO DO NOT ADHERE TO GUIDELINES FOR ANNUAL SCREENING
![Page 23: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/23.jpg)
Risk Assessment
• CLAUS MODEL -
The Claus model takes into account 1st and 2nd degree relatives effected by breast cancer and accounts for their ages at the time of diagnosis
![Page 24: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/24.jpg)
Concepts of Screening
• Merely finding a cancer earlier does not mean the patient will benefit
• A different level of proof is required for a screening test as compared to applying a test to someone who is already ill, because the vast majority of those who will be screened will not have the disease most will not benefit from the test, but many may have false positives studies which may ‘harm them’.
• Since there are cancers that never kill and cancers that are• destined to kill before they can be discovered only a randomized
control trial (RCT) in which one group is screened and the other has the ‘usual’ care can prove a screening test is efficacious
![Page 25: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/25.jpg)
RCT
• The statistical power of the RCT is crucial.
![Page 26: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/26.jpg)
Screening
• Current screening methodologies rely heavily on imaging
![Page 27: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/27.jpg)
Calcifications
![Page 28: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/28.jpg)
![Page 29: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/29.jpg)
![Page 30: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/30.jpg)
Screening
• Cancers detected by periodic screening are likely to be slower growing, more indolent cancers. Faster, more aggressive cancers become clinically evident between screens.
![Page 31: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/31.jpg)
Sojourn Time
• The period of time during which a cancer is detectable by a test before it is clinically evident is called the ‘sojourn time’.
![Page 32: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/32.jpg)
Sojourn Time
• In order to intercept the most cancers earlier, the screening interval should be less than half the sojourn time
![Page 33: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/33.jpg)
Screening Mammography
• Basic definitions
• Uses
• Specificity
• Sensitivity
![Page 34: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/34.jpg)
Mammography
• Basics– Identify breast cancer too small to palpate– Identify non-invasive and pre-malignant lesions– Ionizing radiation– Medial-lateral oblique view– Cranial-caudal view– Nipple to pectoralis– FDA approved sites– Screen film vs. digital
![Page 35: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/35.jpg)
Considerations in Choosing a Mammography Site
- FDA certification of technician, medical physicist, radiologist
- BIRAD reporting
- CAD system
- Digital Mammography
![Page 36: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/36.jpg)
Mammography (con’t)
• CAD – computer aided diagnosis– Aids radiologist in detecting abnormalities– 3 available commercial systems– 500 CAD systems in US
Clinical Trial – - Increase overall recall rate- Increase in # of detected cancers
![Page 37: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/37.jpg)
MAMMOGRAPHYDIGITAL VS FILM
![Page 38: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/38.jpg)
Mammography (con’t)
• Uses– Diagnose small, early stage breast ca– Favorable clinical course– Better cancer related survival – Interpreting studies has some biases
• Lead-time bias• Length bias• Overdiagnosis bias• Healthy volunteer bias
![Page 39: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/39.jpg)
Mammography (con’t)
• Specificity– Likelihood of test being normal when cancer
is absent• We want this high• If low then false positives lead to unnecessary
tests.• Exceeds 90%• BIRADS categories
![Page 40: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/40.jpg)
Mammography (con’t)
• Category Assessment Follow-up
• Breast Imaging Reporting and Database System (BI-RADS)
![Page 41: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/41.jpg)
Mammography (con’t)
• BIRADS0 – more info
1 – normal
2 – benign
3 – probably benign
4 – suspicious
5 - malignant
![Page 42: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/42.jpg)
Mammography (con’t)
• Sensitivity– Proportion of breast cancer detected when
cancer is present• Lesion size• Lesion conspicuity• Breast tissue density• Patient age• Hormone status of tumor• Image quality• Skill of radiologist
![Page 43: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/43.jpg)
Mammography (con’t)
• Sensitivity
– Overall 75%
– 54-58% in age <40
– 81-94% in age >65
![Page 44: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/44.jpg)
Mammography (con’t)
• Factors influencing Specificity and Sensitivity– Radiologist interpretation– High breast density– Centralized screening systems– National QA programs– Interval between mammograms– Post-menopausal hormone use– Prior breast surgery– BMI
![Page 45: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/45.jpg)
Mammography (con’t)
• Harms of screening– False negatives– False positives– Radiation exposure– Anxiety– Over diagnosis
![Page 46: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/46.jpg)
Mammography (con’t)
• Evidence of Benefit– Randomized controlled studies– 4 countries– 500,000 women– 9 studies– Different designs– Effect on mortality– Conflicting results
![Page 47: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/47.jpg)
Mammography (con’t)
Cochrane Review- Review of 7 trials- Screening mammography likely reduces breast cancer mortality- magnitude uncertain - ~20% reduction – or 15% relative risk reduction - screening leads to over diagnosis and over treatment
![Page 48: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/48.jpg)
Mammography (con’t)
• For 2000 women invited to screening for 10 years– 1 will have her life prolonged– 10 will be treated unnecessarily
Conclusion – “It is thus not clear whether screening does more good than harm. Woman invited to screening should be fully informed of both benefits and harms.”
![Page 49: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/49.jpg)
UTZ
• As adjunct to mammography
• Inexpensive
• Widely available
• Targeted evaluation– Solid vs. cyst– Benign vs. malignant
![Page 50: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/50.jpg)
UTZ (con’t)
• Image guided biopsy
• Limited screening use– Needs a skilled operator– Lack of standard exam techniques– Lack of standard interpretation criteria– No microCa++
![Page 51: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/51.jpg)
BREAST MRI
• THE BASIC STRENGTH OF BREAST MRI LIES IN THE DETECTION OF CANCER THAT IS OCCULT ON CONVENTIONAL IMAGING SUCH AS MAMMOGRAPHY AND SONOGRAPHY
![Page 52: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/52.jpg)
Background: What is MRI?
• Uses magnetic fields to produce detailed cross-sectional images of tissue structures
• Uses injected contrast agents to distinguish fat, glandular tissue, lesions, etc. in the breast
• Different factors contribute to the measured signal that determines the brightness of the tissues in the
image• Contrast agent provides reliable detection of cancers
and other lesions.• Screening MRI requires appropriate techniques and
equipment (including dedicated breast MRI equipment) and experienced staff
![Page 53: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/53.jpg)
MRI
• MRI is not a screening technique for average risk patients
![Page 54: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/54.jpg)
MRI
• With IV gadolinium– 83-100% sensitive with cancer above a few
mm– Average 96% sensitive
![Page 55: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/55.jpg)
MRI (con’t)
• Pros and cons– Cost– Lack of standard exam– Lack of standard interpretation criteria– No micro Ca++– Variability of equipment– Increase in false + rate– Availability of equipment
![Page 56: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/56.jpg)
MRI
• Sensitivity - 71-100%
• Specificity - 37 - 97%
• Not recommended for screening– Breast implants– Masses after surgery or XRT– Occult lesions with metastasis– Pre-operative planning?
![Page 57: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/57.jpg)
![Page 58: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/58.jpg)
![Page 59: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/59.jpg)
![Page 60: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/60.jpg)
Evidence
• Since the 2003 guideline, at least 6 prospective, non-randomized studies were conducted, in 6 different countries
• All studies measured benefit of adding annual MRI to mammography
• All study participants had either a BRCA mutation or a strong family history
• Some studies included women with a personal history of breast cancer
• Some studies also included ultrasound and/or CBE• All 6 studies reported significantly higher sensitivity for
MRI compared to mammography (and US, CBE), and lower specificity (i.e. more false positives)
![Page 61: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/61.jpg)
Rationale
• New evidence supporting MRI screening• Ability of MRI to detect cancers is much higher (double)
than mammography• MRI plus mammography detects more cancers than MRI
alone• High false positive rate of MRI makes it inappropriate for
screening women at average risk• Strong evidence for MRI screening of women at
increased risk based on family history/genetics• Insufficient evidence to recommend for or against MRI
screening of women at moderately increased risk based on clinical factors
• Insufficient evidence for other technologies
![Page 62: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/62.jpg)
Limitations and Potential Harms
• False negatives• False positives• Anxiety, psychological distress• More call-backs• More biopsies• Cost• Limited access to high quality MRI screening and MRI-guided
biopsies• Variation in performance, interpretation, recall rates, and expertise• Little or no data on recurrence, survival rates, age, when to start and
stop screening, screening intervals• Variation in insurance coverage
![Page 63: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/63.jpg)
BREAST CANCER SCREENINGWITH MRI
• Individuals with BRCA1 or BRCA2 mutation• Individuals with a 1st degree relative of a BRCA1 or BRCA2 carrier but have
not been tested• Individuals with a lifetime risk of breast cancer of >20%• Individuals that have had radiation therapy to the chest between the ages of
10 and 30 years old• Breast cancer in a male relative• One first degree relative with bilateral breast cancer• Individuals consider at high familial risk:• Two or more first degree relatives with breast cancer or• One 1st degree relative and two or more 2nd or 3rd degree relatives with
breast cancer or• One 1st degree relative with breast cancer before the age of 45 years and
one other relative with breast cancer or• One first degree relative with breast cancer and one or more relatives with
ovarian
![Page 64: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/64.jpg)
Other modalities
• Not FDA-approved for screening– Ductoscopy/ductal lavage– Tomography– Scinitimammography– PET– Elastography– Spectroscopy– Optical imaging– Electrical impendence measurements– Thermography– Etc.
![Page 65: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/65.jpg)
Ductoscopy/Lavage
• The majority of breast cancers originate in the breast duct system so evaluating this system visually with ductoscopy, or studies to evaluate the cells from the ducts may help detect transformation from healthy to malignant cells.
![Page 66: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/66.jpg)
Ductal Lavage
• Asymptomatic women
• High risk
• Use alone or in combination with mammography
![Page 67: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/67.jpg)
High Risk Patients
• Identify High Risk patients
– 2 or more relatives with breast or ovarian ca– Breast ca before age 50 in a relative– Male relative with breast ca– Genetic profiles– Chest radiation
![Page 68: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/68.jpg)
Who is at High Risk?• Three approaches:
#1 - Family history suggestive of inherited gene mutation; risk is calculated by assessment models/tools
#2 - Genetic testing for mutation in BRCA1/2, TP53, or PTEN
#3 - Review of clinical history-Treated for Hodgkin disease -LCIS, ALH-ADH, DCIS-High mammographic density-Personal history of breast cancer
![Page 69: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/69.jpg)
High Risk (con’t)
• Screening options
– Initiate screening at age 30– Shorter intervals– MRI– UTZ
Insufficient evidence exists
![Page 70: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/70.jpg)
High Risk (con”t)
• Who is at high risk?
• Family History
• Clinical Indicators
• MRI screening studies
• Evidence of efficacy
• Benefits, limitations, and potential harms
![Page 71: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/71.jpg)
High Risk (con’t)
• Current ACS Recommendation for Women at Increased Risk for Breast Cancer (2003)
-In the absence of sufficient evidence to recommend specific screening strategies that might benefit women at increased risk, options are provided:
-earlier initiation of screening (30 years or younger)
-the addition of MRI and/or Ultrasound to screening mammography and physical examination.
![Page 72: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/72.jpg)
Early Detection
• There is no certain way to prevent breast cancer.
• The best plan for women at average risk is to follow the American Cancer Society guidelines for early detection.
• Nine out of 10 women can survive breast cancer simply by detecting it early
![Page 73: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/73.jpg)
Bottom Line
• Age and gender are the main risk factors.• Early detection increases survival and• treatment options.• All women 40+ should talk to their doctors• about annual mammograms and CBEs. They• can also perform monthly BSEs.• Mammograms can save lives.
![Page 74: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/74.jpg)
Early Detection/Guidelines
• Age 40+: Annual mammogram, annual clinical breast exam (CBE) by a health care professional, and an optional monthly breast self-exam (BSE).
• Ages 20-39: Every three years a CBE by a health care professional and an optional monthly BSE.
• Women with a family history of breast cancer should talk to their doctor about when to start screening
![Page 75: Breast Cancer Screening](https://reader035.fdocuments.in/reader035/viewer/2022062500/56814f37550346895dbcd547/html5/thumbnails/75.jpg)
American Cancer Society
• GUIDELINES FOR THE EARLY DETECTION OF CANCER
-Yearly mammograms are recommended starting at age 40 and continuing for as long as a woman is in good health.
-Clinical breast exam (CBE) should be part of a periodic health exam, about every 3 years for women in their 20s and 30s and every year for women 40 and over.
-Women should know how their breasts normally feel and report any breast change promptly to their health care providers. Breast self-exam (BSE) is an option for women starting in their 20s.
- Women at high risk (greater than 20% lifetime risk) should get an MRI and a mammogram every year. Women at moderately increased risk (15% to 20% lifetime risk) should talk with their doctors about the benefits and limitations of adding MRI screening to their yearly mammogram. Yearly MRI screening is not recommended for women whose lifetime risk of breast cancer is less than 15%.